前列腺癌筛查：我们能从随机试验中学到什么？
Prostate cancer screening: what can we learn from randomised trials?
作者信息
Auvinen Anssi
机构信息
Faculty of Social Sciences/Health Sciences, University of Tampere, Tampere, Finland.
出版信息
Transl Androl Urol. 2018 Feb;7(1):12-17. doi: 10.21037/tau.2017.12.13.
Abstract
In this article, the principle of randomised trials are first described and then prostate cancer screening trials published to date are evaluated based on these principles. A summary of the randomised prostate cancer screening is provided. The conclusion that can be made from the results of the screening trials, as well as limitations of the evidence and open questions are outlined in the end.
摘要
在本文中，首先描述了随机试验的原则，然后根据这些原则对迄今为止发表的前列腺癌筛查试验进行评估。提供了随机前列腺癌筛查的总结。最后概述了从筛查试验结果中可以得出的结论，以及证据的局限性和未解决的问题。
相似文献
1
Prostate cancer screening: what can we learn from randomised trials?
Transl Androl Urol. 2018 Feb;7(1):12-17. doi: 10.21037/tau.2017.12.13.
2
Screening for prostate cancer.
Cochrane Database Syst Rev. 2006 Jul 19(3):CD004720. doi: 10.1002/14651858.CD004720.pub2.
3
Screening for prostate cancer: a Cochrane systematic review.
Cancer Causes Control. 2007 Apr;18(3):279-85. doi: 10.1007/s10552-006-0087-6. Epub 2007 Jan 6.
4
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
PLoS One. 2019 Nov 5;14(11):e0224479. doi: 10.1371/journal.pone.0224479. eCollection 2019.
5
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group.
Eur J Cancer. 1999 Feb;35(2):262-71. doi: 10.1016/s0959-8049(98)00379-7.
6
Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
Eur Urol Focus. 2019 Mar;5(2):186-191. doi: 10.1016/j.euf.2017.07.007. Epub 2017 Aug 10.
7
Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial.
Eur J Cancer. 2001 Nov;37(17):2154-60. doi: 10.1016/s0959-8049(01)00288-x.
8
The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.
Health Technol Assess. 2015 Oct;19(87):i-xxxi, 1-191. doi: 10.3310/hta19870.
9
[The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation].
Ned Tijdschr Geneeskd. 2005 Apr 30;149(18):966-71.
10
Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies.
Recent Results Cancer Res. 2014;202:65-71. doi: 10.1007/978-3-642-45195-9_8.
引用本文的文献
1
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
PLoS One. 2019 Nov 5;14(11):e0224479. doi: 10.1371/journal.pone.0224479. eCollection 2019.
本文引用的文献
1
The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.
2
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.
3
A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Eur J Epidemiol. 2017 Jun;32(6):521-527. doi: 10.1007/s10654-017-0292-5. Epub 2017 Jul 31.
4
Equipoise in Research: Integrating Ethics and Science in Human Research.
JAMA. 2017 Feb 7;317(5):525-526. doi: 10.1001/jama.2017.0016.
5
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer.
J Urol. 2017 Jul;198(1):50-57. doi: 10.1016/j.juro.2017.01.048. Epub 2017 Jan 16.
6
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.
7
What explains the differences between centres in the European screening trial? A simulation study.
Cancer Epidemiol. 2017 Feb;46:14-19. doi: 10.1016/j.canep.2016.11.005. Epub 2016 Nov 24.
8
Impact of cause of death adjudication on the results of the European prostate cancer screening trial.
Br J Cancer. 2017 Jan 3;116(1):141-148. doi: 10.1038/bjc.2016.378. Epub 2016 Nov 17.
9
Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies.
PLoS One. 2016 Jul 11;11(7):e0159267. doi: 10.1371/journal.pone.0159267. eCollection 2016.
10
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.
Oncologist. 2016 Jun;21(6):716-22. doi: 10.1634/theoncologist.2015-0336. Epub 2016 May 5.
Zotero 插件